Surgery Partners SGRY Q1 2026 Earnings Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy SGRY?
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGRY
Wall Street analysts forecast SGRY stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 14.440
Low
18.00
Averages
26.30
High
36.00
Current: 14.440
Low
18.00
Averages
26.30
High
36.00
About SGRY
Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of approximately 162 surgical facilities comprised of 175 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 30 states, including short-stay surgical hospitals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surgery Partners Q1 2026 Earnings Call Insights
- Stable Revenue Performance: In Q1 2026, Surgery Partners reported approximately $811 million in net revenue with a 4.4% year-over-year growth, indicating a gradual recovery and stabilization of operations following pressures experienced at the end of 2025.
- EBITDA and Margin: The adjusted EBITDA for the quarter was $102 million, resulting in an EBITDA margin of 12.6%, aligning with expectations for the seasonally lower first quarter, which reflects progress in cost management and operational efficiency.
- Investment in Surgical Robots: The company operates 73 surgical robots, contributing to a 14.6% year-over-year growth in total joints performed, which not only enhances service capabilities but also strengthens its competitive position in a challenging market.
- Future Outlook and Acquisition Plans: Management reiterated full-year 2026 revenue guidance of $3.35 billion to $3.45 billion while actively pursuing a key acquisition opportunity in a larger surgical hospital market, expected to be announced in mid-2026, demonstrating confidence in future growth prospects.
See More
Surgery Partners SGRY Q1 2026 Earnings Transcript
See More
Surgery Partners Q1 Earnings Beat Expectations with Revenue Growth
- Revenue Growth: Surgery Partners reported Q1 revenue of $810.9 million, reflecting a 4.5% year-over-year increase, exceeding market expectations by $12.97 million, indicating the company's sustained growth potential in the healthcare sector.
- Same-Facility Metrics: Same-facility revenues rose by 4.4%, while same-facility cases increased by 0.6%, demonstrating the company's ability to expand its business steadily on existing operations, thereby enhancing its competitive position in the market.
- Net Loss Overview: The company recorded a net loss of $35.9 million for Q1; however, adjusted EBITDA reached $102.3 million, reflecting improvements in cost control and operational efficiency despite ongoing losses.
- 2026 Guidance: Surgery Partners reaffirmed its full-year 2026 revenue guidance to be between $3.35 billion and $3.45 billion, with adjusted EBITDA of at least $530 million, showcasing management's confidence in future growth and the stability of its strategic planning.
See More
Surgery Partners Set to Announce Q1 Earnings with Mixed Estimates
- Earnings Announcement: Surgery Partners (SGRY) is set to release its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at -$0.14, reflecting a 53.3% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The revenue estimate stands at $797.93 million, representing a 2.8% year-over-year growth, despite downward revisions, showcasing the company's resilience in the healthcare sector.
- Historical Performance: Over the past two years, SGRY has beaten EPS and revenue estimates 63% of the time, demonstrating consistency in financial performance and maintaining market confidence.
- Future Projections: Surgery Partners has outlined a revenue target of $3.35 billion to $3.45 billion for 2026, indicating a commitment to long-term growth strategies while advancing portfolio optimization.
See More
Surgery Partners to Release Q1 2026 Results and Host Conference Call
- Earnings Release Schedule: Surgery Partners plans to announce its Q1 2026 financial results before the market opens on May 5, 2026, which is expected to provide investors with insights into the company's operational status and financial performance, aiding market analysis of future growth potential.
- Conference Call Details: The company will host a conference call at 8:30 a.m. Eastern Time, allowing investors to participate by dialing 1-877-451-6152 domestically or 1-201-389-0879 internationally, ensuring transparency and enhancing communication with stakeholders.
- Replay Information: A replay of the conference call will be available three hours after the call and until May 19, 2026, with domestic and international numbers being 1-844-512-2921 and 1-412-317-6671 respectively, facilitating access for investors who could not attend live.
- Company Background: Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners operates over 200 healthcare service locations across 30 states, focusing on high-quality, cost-effective surgical and ancillary care solutions, highlighting its significant position in the rapidly growing healthcare services market.
See More
Surgery Partners Reports 4.2% Decline in Q4 Adjusted EBITDA
- Financial Performance Discrepancy: Surgery Partners reported an Adjusted EBITDA of $136.4 million for Q4 2025, reflecting a 4.2% decline compared to the previous year, starkly contrasting with management's prior guidance of margin expansion, leading to a significant drop in stock price and raising concerns about financial transparency among investors.
- Market Reaction: Despite management highlighting a 6.1% growth and a 16.6% margin in Q3, the failure to meet expectations in Q4 resulted in a sharp decline in SGRY shares, indicating a weakened market confidence in the company's future profitability.
- Legal Investigation: Levi & Korsinsky, LLP is investigating potential securities law violations due to the significant discrepancies in financial reporting, encouraging affected shareholders to submit their information to protect their legal rights, which underscores investor concerns regarding corporate governance.
- Investor Losses: Affected shareholders are urged to contact legal counsel for potential compensation, reflecting a crisis of trust in the company's financial reporting and investor relations, which may negatively impact future financing and market performance.
See More
Surgery Partners Q1 2026 Earnings Call Insights
- Stable Revenue Performance: In Q1 2026, Surgery Partners reported approximately $811 million in net revenue with a 4.4% year-over-year growth, indicating a gradual recovery and stabilization of operations following pressures experienced at the end of 2025.
- EBITDA and Margin: The adjusted EBITDA for the quarter was $102 million, resulting in an EBITDA margin of 12.6%, aligning with expectations for the seasonally lower first quarter, which reflects progress in cost management and operational efficiency.
- Investment in Surgical Robots: The company operates 73 surgical robots, contributing to a 14.6% year-over-year growth in total joints performed, which not only enhances service capabilities but also strengthens its competitive position in a challenging market.
- Future Outlook and Acquisition Plans: Management reiterated full-year 2026 revenue guidance of $3.35 billion to $3.45 billion while actively pursuing a key acquisition opportunity in a larger surgical hospital market, expected to be announced in mid-2026, demonstrating confidence in future growth prospects.
See More
Surgery Partners SGRY Q1 2026 Earnings Transcript
See More
Surgery Partners Q1 Earnings Beat Expectations with Revenue Growth
- Revenue Growth: Surgery Partners reported Q1 revenue of $810.9 million, reflecting a 4.5% year-over-year increase, exceeding market expectations by $12.97 million, indicating the company's sustained growth potential in the healthcare sector.
- Same-Facility Metrics: Same-facility revenues rose by 4.4%, while same-facility cases increased by 0.6%, demonstrating the company's ability to expand its business steadily on existing operations, thereby enhancing its competitive position in the market.
- Net Loss Overview: The company recorded a net loss of $35.9 million for Q1; however, adjusted EBITDA reached $102.3 million, reflecting improvements in cost control and operational efficiency despite ongoing losses.
- 2026 Guidance: Surgery Partners reaffirmed its full-year 2026 revenue guidance to be between $3.35 billion and $3.45 billion, with adjusted EBITDA of at least $530 million, showcasing management's confidence in future growth and the stability of its strategic planning.
See More
Surgery Partners Set to Announce Q1 Earnings with Mixed Estimates
- Earnings Announcement: Surgery Partners (SGRY) is set to release its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at -$0.14, reflecting a 53.3% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The revenue estimate stands at $797.93 million, representing a 2.8% year-over-year growth, despite downward revisions, showcasing the company's resilience in the healthcare sector.
- Historical Performance: Over the past two years, SGRY has beaten EPS and revenue estimates 63% of the time, demonstrating consistency in financial performance and maintaining market confidence.
- Future Projections: Surgery Partners has outlined a revenue target of $3.35 billion to $3.45 billion for 2026, indicating a commitment to long-term growth strategies while advancing portfolio optimization.
See More
Surgery Partners to Release Q1 2026 Results and Host Conference Call
- Earnings Release Schedule: Surgery Partners plans to announce its Q1 2026 financial results before the market opens on May 5, 2026, which is expected to provide investors with insights into the company's operational status and financial performance, aiding market analysis of future growth potential.
- Conference Call Details: The company will host a conference call at 8:30 a.m. Eastern Time, allowing investors to participate by dialing 1-877-451-6152 domestically or 1-201-389-0879 internationally, ensuring transparency and enhancing communication with stakeholders.
- Replay Information: A replay of the conference call will be available three hours after the call and until May 19, 2026, with domestic and international numbers being 1-844-512-2921 and 1-412-317-6671 respectively, facilitating access for investors who could not attend live.
- Company Background: Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners operates over 200 healthcare service locations across 30 states, focusing on high-quality, cost-effective surgical and ancillary care solutions, highlighting its significant position in the rapidly growing healthcare services market.
See More
Surgery Partners Reports 4.2% Decline in Q4 Adjusted EBITDA
- Financial Performance Discrepancy: Surgery Partners reported an Adjusted EBITDA of $136.4 million for Q4 2025, reflecting a 4.2% decline compared to the previous year, starkly contrasting with management's prior guidance of margin expansion, leading to a significant drop in stock price and raising concerns about financial transparency among investors.
- Market Reaction: Despite management highlighting a 6.1% growth and a 16.6% margin in Q3, the failure to meet expectations in Q4 resulted in a sharp decline in SGRY shares, indicating a weakened market confidence in the company's future profitability.
- Legal Investigation: Levi & Korsinsky, LLP is investigating potential securities law violations due to the significant discrepancies in financial reporting, encouraging affected shareholders to submit their information to protect their legal rights, which underscores investor concerns regarding corporate governance.
- Investor Losses: Affected shareholders are urged to contact legal counsel for potential compensation, reflecting a crisis of trust in the company's financial reporting and investor relations, which may negatively impact future financing and market performance.
See More
